Amryt is a global biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for rare and orphan diseases. With a strong and expanding portfolio of commercial and developmental assets, Amryt aims to improve the lives of patients suffering from these debilitating conditions.
The company's commercial business includes four orphan disease products: Myalept (metreleptin), Mycapssa (octreotide capsules), Juxtapid (lomitapide), and Oleogel-S10 (Filsuvez). These treatments address various conditions such as leptin deficiency, acromegaly, and Homozygous Familial Hypercholesterolaemia (HoFH). Amryt also has a promising pre-clinical gene therapy candidate, AP103, which offers potential treatment for patients with Dystrophic Epidermolysis Bullosa (EB).
Generated from the website